Petros Pharmaceuticals, Inc. has disclosed a strategic partnership with Idea Evolver, a technology platform specializing in Rx-to-OTC switches and digital pharmaceutical launch solutions.

Ferring Pharmaceuticals and PharmaBiome, a microbiome translation company based in Zürich, have jointly announced a collaborative research and development

Glycotope GmbH and Evotec SE have recently entered into a collaborative agreement to integrate Glycotope's antibodies with Evotec's immune cell engager platform for the development

Astellas Pharma US, Inc. has obtained approval from the U.S. Food and Drug Administration for the use of CRESEMBA®, an azole antifungal drug, in treating invasive aspergillosis

SpyBiotech, a leading biotechnology company known for its groundbreaking vaccine platform technology targeting infectious diseases, cancer, and chronic conditions, has marked a significant achievement

ArteraAI, a developer specializing in multimodal artificial intelligence (MMAI) predictive and prognostic cancer tools, has announced a strategic collaborative agreement

Novartis has received FDA approval for Fabhalta® (iptacopan), making it the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria. Fabhalta, a Factor B inhibitor, controls red blood

Taiwan Bio and TRACT Therapeutics have recently announced a strategic partnership aimed at advancing cellular therapy to transform the prevention of allograft rejection in solid organ transplants.

BioInvent International AB, publicly traded on Nasdaq Stockholm with the ticker symbol BINV, is a biotech company specializing in the exploration and development of innovative immune-modulatory antibodies for cancer

Petros Pharmaceuticals, Inc. is excited to announce its collaboration with Idea Evolver, a leading technology platform specializing in Rx-to-OTC switches and digital pharmaceutical